Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
7.5
Expiration
Nov 20, 2026
DTE
7d
Moneyness
ITM
Intrinsic
$1.49
IBRX 7.5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $0.35 | +16.67% | 10 | 24 |
| Nov 20, 2026 | 7d | $0.48 | -7.69% | 1 | 130 |
| Nov 27, 2026 | 14d | $0.81 | +5.19% | 56 | 222 |
| Dec 4, 2026 | 21d | $1.00 | +11.11% | 2 | 1,106 |
| Dec 11, 2026 | 28d | $0.95 | +0.00% | 7 | 8 |
| Dec 24, 2026 | 41d | — | — | 0 | 4 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Jan 15, 2027 | 63d | $1.15 | +0.88% | 14 | 22,986 |
| Jan 21, 2028 | 434d | $2.56 | +2.40% | 5 | 9,718 |
IBRX Nearby Strikes · Nov 20, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 4.5 P | $0.05 | +0.00% | 20 | 20 | OTM |
| 5 P | $0.10 | +100.00% | 10 | 354 | OTM |
| 5.5 P | $0.15 | +0.00% | 1 | 3 | OTM |
| 6 P | $0.10 | -41.18% | 20 | 4,487 | OTM |
| 6.5 P | $0.18 | -33.33% | 3 | 519 | ITM |
| 7 P | $0.39 | +34.48% | 99 | 4,908 | ITM |
| 7.5 P | $0.48 | -7.69% | 1 | 130 | ITM |
| 8 P | $0.80 | +5.26% | 89 | 3,675 | ITM |
| 8.5 P | $1.10 | +2.80% | 1 | 150 | ITM |
| 9 P | $1.38 | +35.29% | 38 | 1,517 | ITM |
| 9.5 P | $1.70 | -6.08% | 4 | 2 | ITM |
| 10 P | $2.20 | +2.33% | 22 | 680 | ITM |
| 10.5 P | — | — | 0 | 0 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.